Genomadix’s technology has grown and changed to fit industry needs since the company’s inception in 2005. Below is a timeline of our accomplishments and milestones that has led to the creation of the Genomadix CUBE as you know it today.
Submitted the COVID-19 System to Health Canada for assessment to provide authorization to sell in Canada.
European Commercialization Launch: five distributors signed in Europe.
The TAILOR-PCI study is published in JAMA, featuring the use of the Genomadix RX CYP2C19 Test.
Genomadix CUBE receives CE IVD Certification.
Genomadix CUBE is announced.
The Genomadix Legionella Test launched.
Canada and Korea approve the Genomadix RX CYP2C19 Test.
Genomadix RX receives FDA clearance.
Genomadix RX Technology used in POPular Genetics, 2,488 patient trial.
Genomadix RX receives CE Marking for Europe, Africa, Asia.
Genomadix RX CYP2C19 test introduced.
Genomadix DX DNA Analyzer launched.
Genomadix was founded.